The Federal Court recently issued a decision in a patent infringement action pursuant to Section 6(1) of the Patented Medicines (Notice of Compliance) Regulations relating to silodosin. Although the court found that the patent was not invalid on the basis of obviousness, it also found that the patent had not been infringed.

The High Court's first patent decision of 2021 has seen the first full consideration of the Supreme Court's judgment in Regeneron v Kymab. Mr Justice Birss has refined the insufficiency principles established by the Supreme Court in Regeneron, clarifying that the level of precision which businesses must provide when disclosing their inventions applies to patented processes as well as products. This decision provides clarity which will likely be welcomed by the life sciences sector.